A 620-mile geological enigma that has baffled scientists for decades has finally been solved. The Denali Fault, a massive ...

Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...

The primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo.

Stay connected with TTG Media's Noticeboard – your go-to space for industry updates, announcements, and community news from ...

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data ...

Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...

To commemorate the 25th anniversary of Denali, GMC is offering customers a special 25th Anniversary Denali Package available ...

HAL is planning a $70 million expansion over the next three years, including the construction of a new guestroom building.

Denali Therapeutics said the latest trial of its treatment for amyotrophic lateral sclerosis, or ALS, didn't meet its primary or secondary endpoints after 24 weeks.